Brief: Syncona Notes ‍Autolus Therapeutics' Initial Data From MCARTY Phase I Study

Syncona

11/12/2023 07:41

Dec 11 (Reuters) - Syncona Ltd  SYNCS.L :
    * SYNCONA LIMITED  - AUTOLUS PRESENTS CLINICAL DATA UPDATES
    * SYNCONA - INITIAL DATA FROM MCARTY PHASE I STUDY OF AUTO8
SHOW
THERAPY WAS WELL TOLERATED WITH RESPONSES OBSERVED IN ALL
PATIENTS
    * SYNCONA-POOLED ANALYSIS FROM PIVOTAL FELIX STUDY OF
OBE-CEL IN
ADULT ALL SHOWS THERAPY HAS DIFFERENTIATED SAFETY PROFILE WITH
LOW RATES OF SEVERE TOXICITY
    * SYNCONA:POOLED ANALYSIS FROM PIVOTAL FELIX STUDY OF
OBE-CEL IN
ADULT ALL SHOWS HAS CONTINUED HIGH RESPONSE RATES AND PROLONGED
EVENT FREE SURVIVAL

Source text for Eikon:  ID:nRSK3130Wa 
Further company coverage:  SYNCS.L 

 ((Reuters.Briefs@thomsonreuters.com;))